Novostia SA

Based in Switzerland, Novostia SA specializes in developing innovative artificial heart valves, particularly for the aortic and mitral valves, aiming to address critical medical needs in cardiovascular care. Founded in 2017 in Lausanne, Switzerland, Novostia SA focuses on creating advanced artificial heart valves. The company has completed 3 deals, with its most recent funding round occurring on September 17, 2024, raising CHF 5. 6 million.

The founders include Geoffroy Lapeyre, who has a notable history in the medical technology sector, and Alain Barbal serves as the CEO. Novostia specializes in the development of innovative artificial heart valves, specifically designed for the aortic and mitral valves. Their flagship product, the Triflo valve, addresses significant unmet medical needs in the cardiovascular domain, catering to patients of all ages, including children. Characterized by low thrombogenicity, lifelong durability, and low acoustic signature, this valve represents a transformative option for heart valve replacement or repair.

Currently in investigational stages, the technology anticipates first-in-human clinical trials, showcasing Novostia's commitment to advancing healthcare solutions. The primary customer base includes hospitals and healthcare providers across Europe and potentially other international markets as the product progresses through clinical evaluations and approvals. Operating on a business-to-business (B2B) model, Novostia engages with hospitals and medical institutions as clients for its artificial heart valves. Revenue is derived from partnerships and sales agreements upon receiving regulatory approval.

The transactions are structured around supplying medical devices, focusing on equipping hospitals for surgical procedures involving heart valve replacements. The pricing strategy for Novostia's products is anticipated to align with industry standards for advanced cardiovascular devices, reflecting the unique technological advancements of their flagship Triflo valve. As the company advances through clinical trials, it is poised to establish pricing structures that correspond to the clinical value and potential health outcomes associated with their innovative offerings. In September 2024, Novostia SA raised CHF 5.

6 million in venture funding from unspecified investors. The company plans to utilize this funding to support its development strategies and clinical studies. Future growth initiatives include the development of new products, with the Triflo valve expected to make significant advancements as clinical trials begin. Additionally, Novostia aims to expand its presence beyond Europe, targeting new markets globally as regulatory approvals are achieved.